Craig-Hallum Maintains Buy on Fennec Pharmaceuticals, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Chase Knickerbocker maintains a Buy rating on Fennec Pharmaceuticals (NASDAQ:FENC) but lowers the price target from $17 to $15.
August 14, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Craig-Hallum analyst Chase Knickerbocker maintains a Buy rating on Fennec Pharmaceuticals but lowers the price target from $17 to $15.
The maintained Buy rating suggests continued confidence in Fennec Pharmaceuticals' prospects, but the lowered price target indicates some tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100